203 related articles for article (PubMed ID: 26553648)
1. Anti-proliferative activity and cell cycle arrest induced by evodiamine on paclitaxel-sensitive and -resistant human ovarian cancer cells.
Zhong ZF; Tan W; Wang SP; Qiang WA; Wang YT
Sci Rep; 2015 Nov; 5():16415. PubMed ID: 26553648
[TBL] [Abstract][Full Text] [Related]
2. Evodiamine Prevents Glioma Growth, Induces Glioblastoma Cell Apoptosis and Cell Cycle Arrest through JNK Activation.
Wu WS; Chien CC; Liu KH; Chen YC; Chiu WT
Am J Chin Med; 2017; 45(4):879-899. PubMed ID: 28514905
[TBL] [Abstract][Full Text] [Related]
3. Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer.
Nguyen TM; Shin IW; Lee TJ; Park J; Kim JH; Park MS; Lee EJ
Gynecol Oncol; 2016 Mar; 140(3):545-53. PubMed ID: 26691219
[TBL] [Abstract][Full Text] [Related]
4. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
5. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
Zhu X; Li Y; Xie C; Yin X; Liu Y; Cao Y; Fang Y; Lin X; Xu Y; Xu W; Shen H; Wen J
Int J Cancer; 2014 Sep; 135(6):1286-96. PubMed ID: 24510775
[TBL] [Abstract][Full Text] [Related]
6. Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429.
Guo Q; Lu L; Liao Y; Wang X; Zhang Y; Liu Y; Huang S; Sun H; Li Z; Zhao L
Cell Death Dis; 2018 Jan; 8(1):e3178. PubMed ID: 29324735
[TBL] [Abstract][Full Text] [Related]
7. Evodiamine from Evodia rutaecarpa induces apoptosis via activation of JNK and PERK in human ovarian cancer cells.
Chen TC; Chien CC; Wu MS; Chen YC
Phytomedicine; 2016 Jan; 23(1):68-78. PubMed ID: 26902409
[TBL] [Abstract][Full Text] [Related]
8. Activation of JNK contributes to evodiamine-induced apoptosis and G2/M arrest in human colorectal carcinoma cells: a structure-activity study of evodiamine.
Chien CC; Wu MS; Shen SC; Ko CH; Chen CH; Yang LL; Chen YC
PLoS One; 2014; 9(6):e99729. PubMed ID: 24959718
[TBL] [Abstract][Full Text] [Related]
9. Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo.
Liao CH; Pan SL; Guh JH; Chang YL; Pai HC; Lin CH; Teng CM
Carcinogenesis; 2005 May; 26(5):968-75. PubMed ID: 15705600
[TBL] [Abstract][Full Text] [Related]
10. Metformin and epithelial ovarian cancer therapeutics.
Patel S; Kumar L; Singh N
Cell Oncol (Dordr); 2015 Oct; 38(5):365-75. PubMed ID: 26266765
[TBL] [Abstract][Full Text] [Related]
11. Induction of apoptosis by evodiamine involves both activation of mitotic arrest and mitotic slippage.
Zhu LH; Bi W; Liu XD; Li JF; Wu YY; Du BY; Tan YH
Oncol Rep; 2011 Dec; 26(6):1447-55. PubMed ID: 21887472
[TBL] [Abstract][Full Text] [Related]
12. A potential anti-tumor herbal medicine, Corilagin, inhibits ovarian cancer cell growth through blocking the TGF-β signaling pathways.
Jia L; Jin H; Zhou J; Chen L; Lu Y; Ming Y; Yu Y
BMC Complement Altern Med; 2013 Feb; 13():33. PubMed ID: 23410205
[TBL] [Abstract][Full Text] [Related]
13. Reversal of paclitaxel resistance in human ovarian cancer cells with redox-responsive micelles consisting of α-tocopheryl succinate-based polyphosphoester copolymers.
Chen FQ; Zhang JM; Fang XF; Yu H; Liu YL; Li H; Wang YT; Chen MW
Acta Pharmacol Sin; 2017 Jun; 38(6):859-873. PubMed ID: 28260803
[TBL] [Abstract][Full Text] [Related]
14. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
[TBL] [Abstract][Full Text] [Related]
15. Evodiamine Exerts an Anti-Hepatocellular Carcinoma Activity through a WWOX-Dependent Pathway.
Hu CY; Wu HT; Su YC; Lin CH; Chang CJ; Wu CL
Molecules; 2017 Jul; 22(7):. PubMed ID: 28708106
[TBL] [Abstract][Full Text] [Related]
16. Liposomal paclitaxel induces apoptosis, cell death, inhibition of migration capacity and antitumoral activity in ovarian cancer.
Faria RS; de Lima LI; Bonadio RS; Longo JPF; Roque MC; de Matos Neto JN; Moya SE; de Oliveira MC; Azevedo RB
Biomed Pharmacother; 2021 Oct; 142():112000. PubMed ID: 34426249
[TBL] [Abstract][Full Text] [Related]
17. KHDRBS3 promotes paclitaxel resistance and induces glycolysis through modulated MIR17HG/CLDN6 signaling in epithelial ovarian cancer.
Wu X; Qiu L; Feng H; Zhang H; Yu H; Du Y; Wu H; Zhu S; Ruan Y; Jiang H
Life Sci; 2022 Mar; 293():120328. PubMed ID: 35051418
[TBL] [Abstract][Full Text] [Related]
18. Acquisition of paclitaxel resistance via PI3K‑dependent epithelial‑mesenchymal transition in A2780 human ovarian cancer cells.
Du F; Wu X; Liu Y; Wang T; Qi X; Mao Y; Jiang L; Zhu Y; Chen Y; Zhu R; Han X; Jin J; Ma X; Hua D
Oncol Rep; 2013 Sep; 30(3):1113-8. PubMed ID: 23807572
[TBL] [Abstract][Full Text] [Related]
19. ClC-3 promotes paclitaxel resistance via modulating tubulins polymerization in ovarian cancer cells.
Feng J; Peng Z; Gao L; Yang X; Sun Z; Hou X; Li E; Zhu L; Yang H
Biomed Pharmacother; 2021 Jun; 138():111407. PubMed ID: 33765585
[TBL] [Abstract][Full Text] [Related]
20. [Effect of hypoxia on the chemotherapeutic sensitivity of human ovarian cancer cells to paclitaxel and its mechanism].
Huang L; Zhang QH; Ao QL; Xing H; Lu YP; Ma D
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):96-100. PubMed ID: 17645840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
